Table 3 Analysis of clinical features
From: The value of lncRNAs as prognostic biomarkers on clinical outcomes in osteosarcoma: a meta-analysis
Outcome | No. of Studies | No. of Participants | OR (95% CI) | P value | Model | Heterogeneity Chi2, P-value, I2 |
|---|---|---|---|---|---|---|
MALAT1 | ||||||
 Age | 3 | 259 | 0.73 (0.43, 1.24) | 0.24 | Fixed | 0.36, 0.84, 0% |
 Gender | 3 | 259 | 0.73 (0.44, 1.20) | 0.21 | Fixed | 0.16, 0.92, 0% |
 Clinical stage | 3 | 259 | 1.48 (0.27, 7.94) | 0.65 | Random | 15.91, 0.0004, 87% |
 Tumor size | 3 | 259 | 0.95 (0.50, 1.81) | 0.89 | Random | 10.77, 0.005, 81% |
 Distant metastasis | 3 | 259 | 1.98 (0.32, 12.05) | 0.46 | Random | 16.26, 0.0003, 88% |
TUG1 | ||||||
 Age | 5 | 294 | 1.2 (0.48, 3.02) | 0.28 | Fixed | 1.97, 0.74, 0% |
 Gender | 5 | 294 | 1.02 (0.62, 1.65) | 0.95 | Fixed | 2.97, 0.56, 0% |
 Clinical stage | 4 | 254 | 4.66 (2.47, 8.79) | <0.00001 | Fixed | 0.45, 0.93, 0% |
 Tumor size | 4 | 254 | 4.07 (2.33, 7.12) | <0.00001 | Fixed | 2.96, 0.4, 0% |
 Distant metastasis | 5 | 294 | 3.53 (1.20, 10.41) | 0.02 | Random | 13.52, 0.009, 70% |
XIST | ||||||
 Age | 2 | 209 | 1.18 (0.44, 3.15) | 0.74 | Random | 2.55, 0.11, 61% |
 Gender | 3 | 249 | 0.91 (0.56, 1.50) | 0.72 | Fixed | 1.56, 0.46, 0% |
 Clinical stage | 3 | 249 | 3.92 (2.31, 6.66) | <0.00001 | Fixed | 0.92, 0.63, 0% |
 Tumor size | 3 | 249 | 1.15 (0.41, 3.23) | 0.80 | Random | 6.74, 0.03, 70% |
 Distant metastasis | 2 | 209 | 3.10 (1.61, 5.95) | 0.0007 | Fixed | 0.58, 0.45, 0% |